COPD: rehabilitation after an exacerbation improves walking and quality of life

After an exacerbation of chronic obstructive pulmonary disease (COPD), pulmonary rehabilitation improves walking capacity and quality of life. An updated Cochrane review covering 40 randomized trials confirms these benefits with high-certainty evidence. It also concludes that rehabilitation probably reduces hospital readmissions, but does not establish a mortality benefit.

Illustration of a supervised walking session in a pulmonary rehabilitation program.
TrainingEditorial illustration, not study data.

A review of widely varying programs

This update adds 20 studies to the previous version and includes 2,825 participants. The trials compared rehabilitation after a COPD exacerbation with usual care without rehabilitation. The literature searches covered publications available up to June 2, 2026.

All programs included at least some exercise training. However, the number of sessions, their intensity, supervision, and the role of patient education varied considerably. Some programs took place in a single setting, while others combined hospital, outpatient, and home settings. The review therefore evaluates a range of care approaches, not a single program.

Strong benefits for walking and quality of life

Across 22 studies involving 1,464 participants, rehabilitation improved the distance covered in the six-minute walk test by an average of 57.79 meters compared with usual care. The confidence interval ranged from 41.68 to 73.91 meters. The evidence is high certainty, but the size of the improvement varied considerably between trials: this average is not a promise of individual results.

Health-related quality of life also improved. Across 12 studies involving 1,118 participants, the total St George’s Respiratory Questionnaire score decreased by an average of 9.05 points, with a decrease indicating improvement. This result exceeds the minimum important difference threshold of four points. Benefits were seen in the activity and disease impact domains, with no demonstrated difference in the symptoms domain.

Probably fewer readmissions, but mortality remains uncertain

For hospital readmissions, 13 studies involving 1,229 participants followed for three to 18 months indicate a probable reduction, with moderate-certainty evidence. However, some trials found no benefit. The abstract does not provide the absolute risks needed to translate the result into a number of hospital admissions avoided.

The conclusion is less certain for mortality. The pooled estimate remains compatible with either a decrease or an increase in deaths. With low-certainty evidence, presenting rehabilitation as a proven way to extend life would therefore go beyond the data.

What this update changes

The conclusions do not change substantially from the previous version. The best-established benefit remains improved exercise capacity and quality of life after a COPD exacerbation, rather than a demonstrated effect on survival.

The heterogeneity of the programs prevents conclusions about an optimal training frequency or intensity. The authors now place the emphasis on organizing accessible care pathways that are feasible over the long term, rather than on another broad comparison of rehabilitation versus no rehabilitation.

Limitations to keep in mind

Only the PubMed abstract was consulted, not the full text. Programs and follow-up durations varied widely. The lack of participant blinding limits the interpretation of subjective outcomes, and several trials had a high risk of reporting bias. According to the abstract, the review had no dedicated funding. Individual conflicts of interest were not checked.

What we can take away

After a COPD exacerbation, rehabilitation provides established benefits for walking and quality of life. It probably reduces hospital readmissions, with no demonstrated mortality benefit.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.